Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (Benepali®) for the Treatment of All Licensed Adult Etanercept Indications in the UK

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.1083
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

GP2015: An Etanercept Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2017English

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Reumatologia
RheumatologyAllergyImmunology
2019English

SAT0199 Switch From Innovator Etanercept to Biosimilar Etanercept in Inflammatory Rheumatic Diseases: The Experience of Cochin University Hospital Paris-France.

2018English

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Rheumatology and Therapy
2019English

547 Effectiveness of Etanercept in the Treatment of Toxic Epidermal Necrolysis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Arthritis Research & Therapy
2019English

Meta-Analysis for Efficacy of Etanercept for Treatment of Psoriatic Arthritis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Pss29 - Secukinumab Versus Etanercept for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Meta-Analysis of Efficacy of Etanercept for Treatment of Psoriatic Arthritis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy